Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 4

Sponsor Class

OTHER 4NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 2NET 1Gastrointestinal 1Endocrine 1

Conditions

Uveal Melanoma 2Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 548pembrolizumab 384Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Has results × Embolization, Therapeutic × Clear all
NCT00661622 2025-05-16

Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF

Thomas Jefferson University

Phase 2 Completed
53 enrolled 12 charts
Dermatologic

Uveal Melanoma

NCT03472586 2025-04-24

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Thomas Jefferson University

Phase 2 Completed
14 enrolled 8 charts
Dermatologic

Uveal Melanoma

NCT01678664 2024-09-25

EVACEL

Federation Francophone de Cancerologie Digestive

Phase 2 Completed
74 enrolled 10 charts
EndocrineNET

Neoplasm Metastasis, Neoplasms, Neuroendocrine Tumors

NCT00335829 2021-08-13

Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Yale University

Phase 2 Completed
26 enrolled 12 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡